Video Library
Combination therapy continues to evolve in the renal-cell carcinoma space. However, along with improved efficacy come the tests of adverse events and their impact on quality of life. Please join Laura Wood, RN, MSN, OCN, Virginia Seery, MSN, RN, ANP-BC, AOCNP, and Megan Price, MSN, APRN, FNP-C, as they discuss the ways in which drug combinations improve outcomes but also present their own set of challenges for patients’ quality of life.
Identification of new actionable targets and driver mutations have revolutionized the treatment of NSCLC
Waiting for biomarker test results ensures the best outcomes in NSCLC.
Describing the road map of the cancer care journey in NSCLC.
There are an ever-growing number of treatment options that are contributing to more successful outcomes and higher survival rates for cancer patients. The number of care providers that cancer patients need during their journey is also expanding. Please join Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss the role of the multidisciplinary care team approach to deliver the best possible treatment for cancer patients.
Nephrectomy is often the initial treatment for renal-cell cancer (RCC), but systemic therapy is frequently required for advanced RCC. Single-agent targeted therapies are only somewhat effective, which led to the development of immunotherapies and combination therapies (which include immunotherapies). Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss the clinical advantages of combination therapies in patients with advanced RCC.
Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their roles and responsibilities within their academic oncology centers as valuable members of a multidisciplinary team that helps patients successfully navigate the spectrum of patient care. They also detail how they apply the principles of patient-centered care to improve outcomes for patients.
The use of targeted agents and immunotherapy has transformed the treatment of NSCLC
Encouraging shared-decision making by NSCLC by educating and counseling patients and their families
Reflex NGS testing is now the standard of care for many patients with NSCLC
The Affordable Care Act touches many areas of the cancer community and the healthcare system. Watch Joanna Fawzy Morales, Esq., CEO of Triage Cancer; and Monica Fawzy Bryant, Esq., COO of Triage Cancer, discuss the future of the Affordable Care Act.
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, discuss their personal experiences with patient support groups for multiple myeloma patients that deal with pharmacy issues, financial problems, management of pain and neuropathy, psychological and nutritional support.
